{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:07:47Z","timestamp":1763017667139},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T00:00:00Z","timestamp":1474070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00432-016-2270-9","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T05:16:49Z","timestamp":1474089409000},"page":"2603-2610","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients"],"prefix":"10.1007","volume":"142","author":[{"given":"Nils","family":"Winkelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Desole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert G.","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Kunert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars-Olof","family":"M\u00fcgge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,17]]},"reference":[{"key":"2270_CR1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1060028016642786","volume":"50","author":"S Afifi","year":"2016","unstructured":"Afifi S, Michael A, Lesokhin A (2016) Immunotherapy: a new approach to treating multiple myeloma with daratumumab and elotuzumab. Ann Pharmacother 50:555\u2013568","journal-title":"Ann Pharmacother"},{"key":"2270_CR2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","volume":"14","author":"KC Anderson","year":"2016","unstructured":"Anderson KC, Alsina M, Atanackovic D et al (2016) NCCN guidelines insights: multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw 14:389\u2013400","journal-title":"J Natl Compr Canc Netw"},{"key":"2270_CR3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2015.23","volume":"50","author":"A Antar","year":"2015","unstructured":"Antar A, Otrock ZK, Kharfan-Dabaja MA et al (2015) G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis. Bone Marrow Transplant 50:813\u2013817","journal-title":"Bone Marrow Transplant"},{"key":"2270_CR4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91\u201397","journal-title":"N Engl J Med"},{"key":"2270_CR5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2013.52","volume":"48","author":"F Awan","year":"2013","unstructured":"Awan F, Kochuparambil ST, Falconer DE et al (2013) Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 48:1279\u20131284","journal-title":"Bone Marrow Transplant"},{"key":"2270_CR6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","volume":"25","author":"F Cavallo","year":"2011","unstructured":"Cavallo F, Bringhen S, Milone G et al (2011) Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 25:1627\u20131631","journal-title":"Leukemia"},{"key":"2270_CR7","first-page":"8000","volume":"34","author":"M Cavo","year":"2016","unstructured":"Cavo M, Palumbo A, Zweegman S et al (2016) Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial). ASCO Meet Abstr 34:8000","journal-title":"ASCO Meet Abstr"},{"key":"2270_CR8","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875\u20131883","journal-title":"N Engl J Med"},{"key":"2270_CR9","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1080\/1042819021000015899","volume":"43","author":"GL Deliliers","year":"2002","unstructured":"Deliliers GL, Annaloro C, Marconi M et al (2002) Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymphoma 43:1957\u20131960","journal-title":"Leuk Lymphoma"},{"key":"2270_CR10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","volume":"27","author":"O Fitoussi","year":"2001","unstructured":"Fitoussi O, Perreau V, Boiron JM et al (2001) A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 27:837\u2013842","journal-title":"Bone Marrow Transplant"},{"key":"2270_CR11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT et al (2015) Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 16:1617\u20131629","journal-title":"Lancet Oncol"},{"key":"2270_CR12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20:295\u2013308","journal-title":"Biol Blood Marrow Transplant"},{"key":"2270_CR13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","volume":"18","author":"M Hamadani","year":"2012","unstructured":"Hamadani M, Kochuparambil ST, Osman S et al (2012) Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant 18:1128\u20131135","journal-title":"Biol Blood Marrow Transplant"},{"key":"2270_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010615.pub2","author":"T Hartmann","year":"2015","unstructured":"Hartmann T, Hubel K, Monsef I et al (2015) Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. Cochrane Database Syst Rev. doi: 10.1002\/14651858.CD010615.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2270_CR15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/152581603321628296","volume":"12","author":"AP Jillella","year":"2003","unstructured":"Jillella AP, Ustun C, Robach E et al (2003) Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection. J Hematother Stem Cell Res 12:155\u2013160","journal-title":"J Hematother Stem Cell Res"},{"key":"2270_CR16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00277-009-0726-6","volume":"88","author":"M Kropff","year":"2009","unstructured":"Kropff M, Liebisch P, Knop S et al (2009) DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib\/dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann Hematol 88:1125\u20131130","journal-title":"Ann Hematol"},{"key":"2270_CR17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA et al (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114:1729\u20131735","journal-title":"Blood"},{"key":"2270_CR18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/leu.2015.225","volume":"30","author":"SK Kumar","year":"2016","unstructured":"Kumar SK, Ma E, Engebretson AE et al (2016) Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. Leukemia 30:995\u2013998","journal-title":"Leukemia"},{"key":"2270_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3\u20139","journal-title":"Leukemia"},{"key":"2270_CR20","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai EK, Bertsch U, Durig J et al (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29:1721\u20131729","journal-title":"Leukemia"},{"key":"2270_CR21","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/leu.2012.138","volume":"26","author":"S Manier","year":"2012","unstructured":"Manier S, Barthelemy M, Fouquet G et al (2012) Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Leukemia 26:2552\u20132554","journal-title":"Leukemia"},{"key":"2270_CR22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty M, Hubel K, Kroger N et al (2014) Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49:865\u2013872","journal-title":"Bone Marrow Transplant"},{"key":"2270_CR23","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","volume":"127","author":"P Moreau","year":"2016","unstructured":"Moreau P, Hulin C, Macro M et al (2016) VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 127:2569\u20132574","journal-title":"Blood"},{"key":"2270_CR24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","volume":"129","author":"HE Oakervee","year":"2005","unstructured":"Oakervee HE, Popat R, Curry N et al (2005) PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755\u2013762","journal-title":"Br J Haematol"},{"key":"2270_CR25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s002770100351","volume":"80","author":"G Perea","year":"2001","unstructured":"Perea G, Sureda A, Martino R et al (2001) Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 80:592\u2013597","journal-title":"Ann Hematol"},{"key":"2270_CR26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V et al (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23:1337\u20131341","journal-title":"Leukemia"},{"key":"2270_CR27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","volume":"18","author":"D Sheppard","year":"2012","unstructured":"Sheppard D, Bredeson C, Allan D, Tay J (2012) Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 18:1191\u20131203","journal-title":"Biol Blood Marrow Transplant"},{"key":"2270_CR28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","volume":"50","author":"A Sureda","year":"2015","unstructured":"Sureda A, Bader P, Cesaro S et al (2015) Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 50:1037\u20131056","journal-title":"Bone Marrow Transplant"},{"key":"2270_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","volume":"5","author":"DR Sutherland","year":"1996","unstructured":"Sutherland DR, Anderson L, Keeney M et al (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5:213\u2013226","journal-title":"J Hematother"},{"key":"2270_CR30","first-page":"35","volume":"8","author":"N Tandon","year":"2016","unstructured":"Tandon N, Ramakrishnan V, Kumar SK (2016) Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol 8:35\u201344","journal-title":"Clin Pharmacol"},{"key":"2270_CR31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M et al (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254\u20131266","journal-title":"Haematologica"},{"key":"2270_CR32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bmt.1703307","volume":"28","author":"AA Toor","year":"2001","unstructured":"Toor AA, van Burik JA, Weisdorf DJ (2001) Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 28:1129\u20131134","journal-title":"Bone Marrow Transplant"},{"key":"2270_CR33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jca.21360","volume":"30","author":"SA Tuchman","year":"2015","unstructured":"Tuchman SA, Bacon WA, Huang LW et al (2015) Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher 30:176\u2013182","journal-title":"J Clin Apher"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2270-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2270-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2270-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:02:34Z","timestamp":1498330954000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2270-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,17]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2270"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2270-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,17]]}}}